Figure 3
![Figure 3](http://media.springernature.com/full/springer-static/image/art%3A10.1186%2F1471-2334-14-465/MediaObjects/12879_2013_Article_3786_Fig3_HTML.jpg)
Change from baseline in FSS total score up to Week 72 for all simeprevir/PR treatment groups combined vs placebo/PR in a) the PILLAR study and b) the ASPIRE study.
Change from baseline in FSS total score up to Week 72 for all simeprevir/PR treatment groups combined vs placebo/PR in a) the PILLAR study and b) the ASPIRE study.